HC Wainwright Reiterates Buy Rating for Silence Therapeutics (NASDAQ:SLN)

Silence Therapeutics (NASDAQ:SLN - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $75.00 target price on the stock.

A number of other brokerages have also recently weighed in on SLN. Morgan Stanley reduced their price objective on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. The Goldman Sachs Group decreased their price target on shares of Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a report on Friday, May 9th. Chardan Capital cut their price objective on Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, BMO Capital Markets cut their price target on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Silence Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $33.83.

Silence Therapeutics Stock Down 5.1%

Shares of SLN traded down $0.27 during mid-day trading on Friday, hitting $5.06. 36,804 shares of the company's stock were exchanged, compared to its average volume of 251,068. Silence Therapeutics has a twelve month low of $1.97 and a twelve month high of $22.47. The firm has a fifty day moving average of $4.13 and a two-hundred day moving average of $4.92. The stock has a market cap of $151.45 million, a price-to-earnings ratio of -3.22 and a beta of 1.41.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The company had revenue of $0.14 million for the quarter, compared to the consensus estimate of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. On average, equities analysts predict that Silence Therapeutics will post -1.77 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Redmile Group LLC boosted its stake in Silence Therapeutics by 26.3% during the fourth quarter. Redmile Group LLC now owns 2,399,317 shares of the company's stock worth $16,507,000 after buying an additional 500,000 shares in the last quarter. Nantahala Capital Management LLC increased its stake in Silence Therapeutics by 424.8% in the fourth quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company's stock valued at $7,222,000 after acquiring an additional 849,676 shares during the period. Point72 Asset Management L.P. raised its position in Silence Therapeutics by 35.3% in the fourth quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company's stock worth $4,356,000 after purchasing an additional 165,300 shares in the last quarter. Cantor Fitzgerald L. P. lifted its stake in Silence Therapeutics by 61.5% during the fourth quarter. Cantor Fitzgerald L. P. now owns 539,726 shares of the company's stock worth $3,713,000 after purchasing an additional 205,534 shares during the period. Finally, Bank of America Corp DE boosted its holdings in Silence Therapeutics by 48,165.6% during the fourth quarter. Bank of America Corp DE now owns 499,066 shares of the company's stock valued at $3,434,000 after purchasing an additional 498,032 shares in the last quarter. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.